Pagoclone Pellets – 10mg
€ 12,50 – € 237,50Price range: € 12,50 through € 237,50
Pagoclone Pellets 10mg are described as compressed research preparations associated with pagoclone, a nonbenzodiazepine compound belonging to the cyclopyrrolone-related chemical family.
Pagoclone has been investigated as a ligand interacting with benzodiazepine-associated binding sites on GABAA receptors.
The supplied source describes solid pressed pellets with a labeled analyte quantity of 10mg per finished unit.
This quantity has not been independently verified through finished-unit testing.
The described scientific context includes chemical identity assessment, chromatographic characterization, physicochemical analysis, and controlled in-vitro investigation of GABAA-associated ligands.
The source reports molecular formula C23H22ClN3O2 and molecular weight approximately 407.90 g/mol for the stated neutral composition.
It also supplies two alternative CAS numbers, 133737-32-3 and 133737-48-1, without confirming their assignments.
Claims concerning purity of approximately 98–99%, third-party testing, batch tracking, and ISO-aligned manufacturing remain unverified.
Chemical identity, finished-unit content, content uniformity, excipients, and storage stability require batch-specific documentation.
The pellets are not established as certified reference materials or validated quantitative calibration standards.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Pagoclone Pellets 10mg – Cyclopyrrolone Research Material
Pagoclone Pellets 10mg – Product Overview
Pagoclone Pellets 10mg is the supplied catalog designation for a compressed-pellet research preparation associated with pagoclone.
Pagoclone is described as a nonbenzodiazepine cyclopyrrolone-related compound investigated in the context of GABAA receptor-associated ligand research.
The supplied source identifies solid pressed pellets containing a labeled quantity of the named compound per finished unit. Pagoclone Pellets – 10mg
This labeled quantity is a source-provided specification rather than an independently confirmed analytical measurement.
No finished-unit assay, content-uniformity study, or batch-specific quantitative report accompanied the information. Pagoclone Pellets – 10mg
The source positions the preparation for controlled analytical and non-clinical laboratory research.
The stated scientific contexts include chemical identification, chromatographic characterization, physicochemical assessment, and investigation of receptor-associated ligands.
These research contexts should not be confused with verified analytical performance of the actual finished pellets.
The supplied information also refers to independent testing, batch records, and Certificate of Analysis documentation.
However, no supporting laboratory certificates or batch-specific analytical results were provided.
The finished preparation is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product. Pagoclone Pellets – 10mg
Chemical Identity & Classification
The supplied source identifies the named compound as pagoclone.
Pagoclone is described as a nonbenzodiazepine cyclopyrrolone-related ligand associated with GABAA receptor research.
The supplied chemical information includes:
- Common designation: Pagoclone
- Reported synonyms: CI-1043, IP-456, RP-59037, RP-62955
- Reported CAS Registry Numbers: 133737-32-3 and 133737-48-1, unresolved
- Reported molecular formula: C23H22ClN3O2
- Calculated molecular weight for that formula: Approximately 407.90 g/mol
- Chemical classification: Nonbenzodiazepine cyclopyrrolone-related compound
- Reported presentation: Solid pressed pellets
- Labeled analyte amount: 10mg per finished pellet
- Intended designation: Research Use Only
The source also supplies the systematic name 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one.
The correspondence between that systematic name, the reported formula, the synonyms, and the two CAS identifiers has not been independently established.
These identifiers should be reconciled against a verified structural record before publication as definitive specifications.
The reported formula corresponds to approximately 407.90 g/mol.
The source also describes a wider molecular-weight range extending to approximately 426.9 g/mol.
That higher value cannot be attributed to the stated neutral formula without specifying a different chemical composition or form.
The actual chemical form and stereochemical identity of the product have not been established.
The molecular identity of the named ingredient does not establish the composition of the finished pellet.
Additional formulation components may be present, but no excipient specification was supplied.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the actual molecular structure, stereochemistry, and chemical form.
Chemical & Physical Characteristics
The supplied source describes the product as off-white to lightly tinted compressed pellets of uniform appearance.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
The reported appearance therefore remains a supplier-provided description.
A compressed pellet is a finished preparation that may contain the named analyte together with additional formulation components. Pagoclone Pellets – 10mg
The source does not identify pellet dimensions, total unit mass, compression characteristics, excipient composition, or manufacturing method.
The named compound is associated with a nonbenzodiazepine molecular framework investigated in GABAA receptor-related research.
The source describes general solubility in common organic solvents.
However, no product-specific solubility measurements, solvent compatibility records, or finished-pellet extraction studies were supplied. Pagoclone Pellets – 10mg
No validated dissolution, recovery, or stability data were provided for the complete preparation.
The source also does not establish whether the analyte is distributed uniformly within each finished pellet.
Consequently, no definitive claim is made about the physical behavior or analytical recovery of the finished preparation.
Purity & Analytical Verification
The supplied source claims typical ingredient purity of approximately 98–99%.
It also refers to independent analytical verification and low impurity levels.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed purity and impurity limits therefore remain unverified.
For Pagoclone Pellets 10mg, ingredient purity and finished-unit composition are separate analytical characteristics.
An ingredient-purity result does not independently establish the actual quantity of analyte in a finished pellet. Pagoclone Pellets – 10mg
Likewise, the labeled analyte amount does not establish content uniformity across a batch.
The source refers to HPLC, LC-MS, and NMR spectroscopy as analytical techniques relevant to characterization.
However, no product-specific results were supplied demonstrating identification, purity assessment, or quantitative recovery of pagoclone from the finished preparation.
The source does not establish a validated quantitative method, assigned reference value, or measurement uncertainty.
The preparation should therefore not be described as a certified quantitative reference standard.
Any definitive claims about purity, identity, composition, or uniformity require supporting analytical records for the actual batch.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, ICH-aligned practices, and ISO-aligned production conditions.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, or ISO certification was supplied.
The claims therefore remain unverified.
For a finished-pellet preparation, batch documentation should distinguish the identity and analytical characteristics of the named ingredient from the characteristics of the complete unit.
The source does not establish whether the labeled analyte quantity was independently measured after formulation.
It also does not provide evidence of finished-unit content uniformity or batch-to-batch consistency.
For Pagoclone Pellets 10mg, the distinction between nominal analyte content and verified finished-unit composition is particularly important. Pagoclone Pellets – 10mg
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, ISO alignment, ICH alignment, and batch consistency should be supported by actual records.
Safety, Handling & Laboratory Precautions
Pagoclone is a nonbenzodiazepine compound associated with GABAA receptor modulation.
Compounds affecting this receptor system may present central nervous system hazards, including sedation and impairment.
The supplied source does not provide a complete product-specific toxicological assessment.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed-pellet presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments. Pagoclone Pellets – 10mg
Because the actual chemical identity, ingredient purity, excipient composition, and finished-unit content have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes light-resistant, moisture-resistant packaging, batch-aware handling, tracking, and professional shipment arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was supplied.
The source recommends storage in a cool, dry, low-humidity environment protected from light.
It also suggests refrigeration at approximately 2–8°C.
No validated stability study was provided for the finished-pellet preparation.
The suggested temperature range therefore cannot be presented as a verified requirement or as evidence of a particular shelf life.
For Pagoclone Pellets 10mg, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The labeled analyte quantity should be recorded as a source-provided specification unless independently verified.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
The supplied scientific context places pagoclone within analytical research involving nonbenzodiazepine compounds, cyclopyrrolone-related chemical structures, and GABAA receptor-associated ligands. Pagoclone Pellets – 10mg
The source describes interest in chromatographic characterization, receptor-related in-vitro studies, and investigation of related chemical families.
However, no product-specific analytical validation, receptor-binding dataset, or stability study was supplied for the actual pellets.
The Raw Lab Chems catalog identifies Pagoclone Pellets as the product listing discussed here.
For related catalog context involving other nonbenzodiazepine research substances, the supplied source also identifies Deschloroetizolam Blotters and Dechloroetizolam Pellets.
These related listings concern a different named chemical family and should not be treated as chemically identical to pagoclone.
The two supplied deschloroetizolam URLs also use different spellings in their slugs.
Those URL spellings have been preserved as supplied, but their destination content has not been independently verified.
The supplied information does not establish equivalent chemical purity, finished-unit content, excipient composition, or analytical performance across these products.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes professional packaging, international shipping, tracking, and secure handling arrangements.
No current inventory record, confirmed pack-size listing, carrier agreement, shipment authorization, or verified delivery information was supplied.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted. Pagoclone Pellets – 10mg
Pagoclone may be subject to pharmaceutical, controlled-substance, analogue, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Pagoclone is a nonbenzodiazepine research compound whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 ,250 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.